
Higher TTMV-HPV DNA levels indicate advanced tumor staging in OPSCC. In this cohort study (n=203), increased pretreatment TTMV-HPV DNA was linked to higher clinical tumor (aOR 2.51, 95% CI, 1.17-5.46) and nodal staging (aOR 4.26, 95% CI, 1.82-10.34). PET-CT findings also correlated with DNA levels. However, no association was found with histopathologic markers or survival, suggesting its role in staging but not prognosis.
Like
Save
Share